Causeway Sensors is a deep-tech startup developing next-generation nanosensors which will enable at-line, real-time process control in bioproduction. The company was founded in 2013, spinning out of Queen’s University Belfast after 10 years of world-class research in nanotechnology, optics and biosensor devices. The company has successfully raised £3.1M in VC funding and £3.5M in competitive grant funding, backed by UKRI. Our beachhead product, Titan, is based on a patented SPR-based sensor platform and is designed to allow accurate, affordable and rapid quantification of IgG, titre, from a variety of sample matrices with minimal sample preparation. The technology miniaturises lab-scale processes into a nanochip that can plug directly into a bioreactor and measure data in real time. The product will be initially aimed at the therapeutic antibody market which manufactures over 16 million litres of product every year. The top-grossing drug, Humira, grossed $22Bn in 2022. In May 2023, Titan was successfully validated at the Centre for Process Innovation (CPI) in Darlington. We are seeking additional validation partners and corporate investors to accelerate the commercialisation of the technology. Our technological roadmap includes: 1) developing additional assays for CQA in biomanufacturing including assessing product quality (affinity, specificity, aggregation) and quantifying impurities (host cell protein, toxins). 2) A 2nd generation device for multiplexing assays on a single chip. The generation of high-quality biomanufacturing data is challenging. Only primitive process parameters are collected in real-time and used to approximate the batch yield. Our technology has the potential to transform biomanufacturing using real-time data and machine learning to map optimum growth conditions to maximise product yields, reduce the risks of spoilt batches, decrease costs and decrease the overall environmental impact of manufacturing life-saving therapies.